Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT )

4.901 -0.169 (-3.33%)
Streaming Delayed Price Updated: 10:19 AM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 44,149
Open 5.050
Bid (Size) 4.890 (9)
Ask (Size) 4.980 (5)
Prev. Close 5.070
Today's Range 4.857 - 5.115
52wk Range 4.750 - 12.10
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing. 
Via Benzinga

Performance

YTD
-40.88%
-40.88%
1 Month
-36.27%
-36.27%
3 Month
-31.45%
-31.45%
6 Month
-26.52%
-26.52%
1 Year
-39.64%
-39.64%

More News

Read More
S&P 500 Moves Lower; US Crude Oil Inventories Increase
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Falls Over 100 Points; US Producer Prices Rise In October
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Edge Lower; Cisco Earnings Top Views
Via Benzinga
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort
Via AB Newswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
Via News Direct
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
From PESG Research
Via Business Wire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via News Direct
Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment
Via News Direct
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
From PESG Research
Via Business Wire
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data
Via News Direct
Exposures Product Safety
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
Via AB Newswire
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
Via AB Newswire
Precision Medicine M&A is Transforming the Future of the Biotech Industry
Via AB Newswire
7 Penny Biotech Stocks to Triple Your Investment
Via InvestorPlace
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
Via InvestorPlace
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
From Nuvectis Pharma, Inc.
Via GlobeNewswire
5 Healthcare Stocks to Buy for 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.